Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033497 · ClinicalTrials.gov registry record · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
A NA study of Brain Tumor, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 101
- Enrollment target
- 2
- Study locations
NCT04033497: Recruiting NA study of Brain Tumor, sponsored by Brigham and Women's Hospital.
NCT04033497 is a NA study of Brain Tumor that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 101 participants, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04033497, a NA study of Brain Tumor, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused radiation has enlarged.
Primary Outcome
The sensitivity along with 95% exact binomial confidence interval of pre-operative treatment response assessment maps for the identification of viable tumor relative to the gold standard of pathologic review
Conditions Studied
Interventions
- DEVICE MRI
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2028-07-01 |
| Phase | NA |
What NCT04033497 shows while recruiting
NCT04033497 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT04033497 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04033497 about?
NCT04033497 is a clinical study titled "Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases". This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused ra...
What is the current status of trial NCT04033497?
This trial is currently recruiting. It is a NA study. The enrollment target is 101 participants. The study started on 2019-08-20. Estimated completion is 2028-07-01.
What conditions does trial NCT04033497 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT04033497?
The interventions under investigation include: MRI (DEVICE).
Who is sponsoring clinical trial NCT04033497?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04033497 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04033497's enrollment target sits among peer trials
101 17th of 69 higher than 53 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
RECRUITING · NA
-
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
RECRUITING · NA
-
Ommaya Reservoir Placement for Brain Tumor Biomarker Access
RECRUITING · NA
-
Mapping of Human Cognition
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
- NCT06942949 · 101 participants · NA
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI